Spinal Cord Injury News and Research

RSS

A spinal cord injury usually begins with a sudden, traumatic blow to the spine that fractures or dislocates vertebrae. The damage begins at the moment of injury when displaced bone fragments, disc material, or ligaments bruise or tear into spinal cord tissue. Most injuries to the spinal cord don't completely sever it. Instead, an injury is more likely to cause fractures and compression of the vertebrae, which then crush and destroy the axons, extensions of nerve cells that carry signals up and down the spinal cord between the brain and the rest of the body. An injury to the spinal cord can damage a few, many, or almost all of these axons. Some injuries will allow almost complete recovery. Others will result in complete paralysis.

Neuralstem ends litigation with ReNeuron

Neuralstem, Inc. announced that it has reach a settlement with ReNeuron, Ltd. ending litigation between the parties.

28 Jan 2011

Taxol drug promotes regeneration of nerve cells in CNS after spinal cord injury: Study

In a study published today in Science, a global research team reports that the cancer drug Taxol promotes the regeneration of injured nerve cells in the central nervous system after spinal cord injury.

28 Jan 2011

As recording technology rapidly improves, neurons give up their secrets cell by cell

Scientists at The Rehabilitation Institute of Chicago (RIC), designated the "#1 Rehabilitation Hospital in America" by U.S. News & World Report since 1991, report that, thanks to improvements in technology and data analysis, our understanding of the functional principles that guide the development and operation of the brain could improve drastically in the next few years.

27 Jan 2011

Spine surgeon successfully treated with RNL Bio's stem cell therapy for Autoimmune Arthritis

RNL BIO CO., LTD, a leading biopharmaceutical company specialized in adult stem cell therapeutics, announced on January 21, 2011 another successful patient report utilizing stem cell therapy on a leading US orthopedic spine surgeon who suffered from Autoimmune Arthritis.

26 Jan 2011

Study validates MultiStem as potential stem cell therapy for spinal cord injury

Case Western Reserve University School of Medicine and Athersys, Inc. announced a joint scientific study on spinal cord injury will be published today in the January issue of The Journal of Neuroscience.

20 Jan 2011

Salk Institute uncovers presenilin's productive side

Mutant presenilin is infamous for its role in the most aggressive form of Alzheimer's disease-early-onset familial Alzheimer's-which can strike people as early as their 30s. In their latest study, researchers at the Salk Institute uncovered presenilin's productive side: It helps embryonic motor neurons navigate the maze of chemical cues that pull, push and hem them in on their way to their proper targets.

19 Jan 2011

Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia

Geron Corporation today announced enrollment of the first patient in a Phase 2 clinical trial to evaluate the activity of the company's telomerase inhibitor drug, imetelstat (GRN163L), in patients with essential thrombocythemia (ET).

19 Jan 2011

Case Western Reserve, Athersys enter partnership for scientific study on spinal cord injury

19 Jan 2011

UAB study uses InQ system to evaluate effects of secondary injury components on brain cells

InQ Biosciences, a provider of innovative technologies for cell growth and research, today announced that a pre-commercial version of its InQ Cell Research System is being utilized in a University of Alabama at Birmingham study evaluating the effects of secondary injury components on brain cells.

19 Jan 2011

Study supports use of telomerase inhibitors for treatment of childhood cancers

Geron Corporation today announced the publication of preclinical data demonstrating that the company's telomerase inhibitor drug, imetelstat (GRN163L), currently in Phase 2 clinical trials, selectively targets cancer stem cells in pediatric tumors of neural origin.

11 Jan 2011

StemCells $10 million common stock offering to close today

StemCells, Inc. announced today that it has entered into an agreement to sell ten million shares of its common stock to selected institutional investors at a price of $1.00 per share, which represents a 10% discount to the closing price per share of January 6. The offering is expected to close today, subject to customary closing conditions, and StemCells expects to receive net proceeds, after deducting offering expenses and fees, of approximately $9.4 million.

7 Jan 2011

First web-based TBI screening tool for veterans

A team of researchers at Mount Sinai School of Medicine has developed the first web-based screening tool for Traumatic Brain Injury. This instrument has recently been used by soldiers returning from the wars in Iraq and Afghanistan who participated in the Sixth Annual Road to Recovery Conference and Tribute in Orlando to determine if they sustained a TBI.

6 Jan 2011

New technology can help implement safe driving strategies in electric wheelchairs

Thick gravel, mud, snow, steep ramps or hills . . . They might get a pedestrian a little dirty or out of breath, but to someone in an electric wheelchair, they could mean terrain that's simply too difficult to cross alone. To address this problem, researchers at the Florida A&M University-Florida State University College of Engineering are working on technology that will enable electric-powered wheelchairs to detect hazardous terrain and automatically adjust their control settings to maneuver more safely.

4 Jan 2011

Stem cell therapy helps patient with diabetes gangrene recover from foot ulcer: ICMS conference

During ICMS Annual International Congress on Regenerative and Cell Based Medicine Conference held on November 12, 2010 in Las Vegas, Nevada, it was announced that a patient with complications of diabetes gangrene recovered from foot ulcer through stem cell therapy.

27 Dec 2010

Military health: Philanthropy, not the Pentagon, leads to quality care for brain-injured soldiers

To see what cognitive therapy looked like, ProPublica and NPR spent several days with McKinney and fellow soldiers and veterans at Project Share, a charity to help brain-damaged soldiers. (This article is part of an ongoing investigation.) The program is based out of the Shepherd Center for Brain and Spinal Cord Injury in Atlanta, a nationally recognized hospital for head injuries (Miller and Zwerdling, 12/21).

22 Dec 2010

Exciting progress made in MS research during 2010

Exciting advances were made in 2010 in virtually every field of MS research. Progress toward finding new therapies for MS is illustrated by the availability of the first oral disease-modifying therapy for MS. Progress was also made toward finding ways to restore function and improving quality of life and specific MS symptoms through exercise, meditation, rehabilitation and medications, including the first therapy specifically approved to treat a symptom of MS (Ampyra).

20 Dec 2010

FVCG invests $175,000 in Celvive for stem cell research in spinal cord injury

Spinal cord injury (SCI) is a devastating neurological condition with limited therapeutic options. In the United States alone, there are more than 250,000 people living with SCI; approximately three million worldwide are affected.

20 Dec 2010

RXi's dermal anti-scarring candidate selected to advance into development

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today announced the selection of its first RNAi therapeutic product candidate to advance into development.

20 Dec 2010

Improved brain-machine technologies

A new study published in the Dec 15 issue of The Journal of Neuroscience found that monkeys were able to move thought-controlled computer cursors more quickly and accurately when provided with additional sensory feedback.

19 Dec 2010

FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression

Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.

17 Dec 2010

Spinal Cord Injury News and Research

Further Reading

Neuralstem ends litigation with ReNeuron

Taxol drug promotes regeneration of nerve cells in CNS after spinal cord injury: Study

As recording technology rapidly improves, neurons give up their secrets cell by cell

Spine surgeon successfully treated with RNL Bio's stem cell therapy for Autoimmune Arthritis

Study validates MultiStem as potential stem cell therapy for spinal cord injury

Salk Institute uncovers presenilin's productive side

Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia

Case Western Reserve, Athersys enter partnership for scientific study on spinal cord injury

UAB study uses InQ system to evaluate effects of secondary injury components on brain cells

Study supports use of telomerase inhibitors for treatment of childhood cancers

StemCells $10 million common stock offering to close today

First web-based TBI screening tool for veterans

New technology can help implement safe driving strategies in electric wheelchairs

Stem cell therapy helps patient with diabetes gangrene recover from foot ulcer: ICMS conference

Military health: Philanthropy, not the Pentagon, leads to quality care for brain-injured soldiers

Exciting progress made in MS research during 2010

FVCG invests $175,000 in Celvive for stem cell research in spinal cord injury

RXi's dermal anti-scarring candidate selected to advance into development

Improved brain-machine technologies

FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News